Page last updated: 2024-11-12
adonifoline
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
adonifoline: isolated from Senecio scandens;structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Senecio | genus | A species of toxic plants of the Compositae. The poisonous compounds are alkaloids which cause cattle diseases, neoplasms, and liver damage and are used to produce cancers in experimental animals.[MeSH] | Asteraceae | A large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH] |
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 15736564 |
| MeSH ID | M0542515 |
Synonyms (8)
| Synonym |
|---|
| adonifoline |
| 115712-88-4 |
| (1r,20r)-4-hydroxy-5,10-dimethyl-2,6,9,12-tetraoxa-17-azapentacyclo[12.5.1.14,8.08,10.017,20]henicos-14-ene-3,11-dione |
| AKOS040760047 |
| FS-6726 |
| (+)-adonifoline |
| HY-N1918 |
| CS-0018229 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " The developed method was successfully applied to the in vivo pharmacokinetic study in rats after intravenous administration of SEN and ADO." | ( Simultaneous determination of senecionine, adonifoline and their metabolites in rat serum by UPLC-ESIMS and its application in pharmacokinetic studies. Gao, J; He, Y; Li, Y; Wang, C; Wang, Z; Xiong, A; Yang, L, 2009) | 0.62 |
| " This study determined the differences in the in vivo pharmacokinetic behavior of senecionine (SEN), adonifoline (ADO), and their main metabolites in rats after intravenous administration and oral administration by ultraperformance liquid chromatography/electrospray ionization mass spectrometry." | ( The comparative pharmacokinetics of two pyrrolizidine alkaloids, senecionine and adonifoline, and their main metabolites in rats after intravenous and oral administration by UPLC/ESIMS. Cheng, X; Gao, J; He, Y; Li, Y; Ma, Y; Wang, C; Wang, Z; Xiong, A; Yang, L, 2011) | 0.81 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Upon intravenous administration and oral administration of SEN and ADO, significant differences in pharmacokinetics were observed, with the SEN and ADO being absorbed fast with lower bioavailability and being quickly metabolized to PA N-oxides and hydroxylation products of PAs or their N-oxides." | ( The comparative pharmacokinetics of two pyrrolizidine alkaloids, senecionine and adonifoline, and their main metabolites in rats after intravenous and oral administration by UPLC/ESIMS. Cheng, X; Gao, J; He, Y; Li, Y; Ma, Y; Wang, C; Wang, Z; Xiong, A; Yang, L, 2011) | 0.6 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "001) for both dosing routes in rats." | ( The comparative pharmacokinetics of two pyrrolizidine alkaloids, senecionine and adonifoline, and their main metabolites in rats after intravenous and oral administration by UPLC/ESIMS. Cheng, X; Gao, J; He, Y; Li, Y; Ma, Y; Wang, C; Wang, Z; Xiong, A; Yang, L, 2011) | 0.6 |
| "26 μg according to the recommended dosage of the preparation." | ( [Quantification of hepatotoxic pyrrolizidine alkaloid adonifoline in traditional Chinese medicine preparations containing Senecionis Scandentis Herba]. Jiang, KY; Ju, ZC; Wang, ZT; Xiong, AZ; Xiong, F; Yang, L, 2020) | 0.81 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||